Skip to main content
Premium Trial:

Request an Annual Quote

MDS Proteomics Buys 2,000 cDNAs from Kazusa DNA Research Institute

NEW YORK, Feb. 5 - MDS Proteomics has acquired roughly 2,000 disease-related, full-length cDNA clones from Japan's Kazusa DNA Research Institute, MDS said on Tuesday.

The three-year deal "is a major step" to help MDS meet its goal of discovering 1,000 new drug targets in the next five years, according to Frank Gleeson, president and CEO of MDS Proteomics.

Financial terms of the agreement were not disclosed.

"This is a further demonstration that MDS Proteomics has moved aggressively to apply its platform to discover new treatments for human diseases," the company said in a statement.

Last month, MDS and rival proteomics firm Cellzome made substantial strides in decoding the yeast proteome. From MDS' side, researchers converted about 10 percent of the yeast genome into bait proteins and detected 3,617 protein interactions. The team identified more than 25 percent of the yeast proteome, including more than 500 new proteins, in a matter of weeks.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.